Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin

Breast Cancer Research and Treatment

Volumn 134, Issue 1, 2012, Pages 117-129

  Abu Ajaj, Khalid ^a,c   Graeser, Ralph ^b,d   Kratz, Felix ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

^b PROQINASE GMBH   (Germany)

^c LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Breast cancer; Doxorubicin; INNO 206 (DOXO EMCH); MDR modulators; Prodrugs; Reversal of multidrug resistance (MDR); Zosuquidar (LY335979)

Indexed keywords

6 MALEIMIDOCAPROYL HYDRAZIDE; ACETYLBENZOIC ACID; ALBUMIN; BENZOIC ACID DERIVATIVE; CYSTEINE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; HYDRAZONE DERIVATIVE; HYDROXYL GROUP; LY 335970; MALEIMIDE HYDRAZONE; PRODRUG; UNCLASSIFIED DRUG; ZOSUQUIDAR; ZOSUQUIDAR DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER CELL; CHEMICAL BOND; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HYDRAZONE BOND; MULTIDRUG RESISTANCE; PH; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DIBENZOCYCLOHEPTENES; DOXORUBICIN; DRUG CARRIERS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG STABILITY; DRUG SYNERGISM; FEMALE; FLUORESCENT DYES; HUMANS; HYDRAZONES; HYDROLYSIS; INHIBITORY CONCENTRATION 50; PRODRUGS; QUINOLINES; RHODAMINE 123; SERUM ALBUMIN;

EID: 84863983999     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1937-9     Document Type: Article

References (45)

1. M Lehnert 1998 Chemotherapy resistance in breast cancer Anticancer Res 18 3C 2225 2226 9703789 1:STN:280:DyaK1czmvFCisA%3D%3D
2. H Thomas HM Coley 2003 Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein Cancer Control 10 2 159 165 12712010
3. RB Wang CL Kuo LL Lien EJ Lien 2003 Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors J Clin Pharm Ther 28 3 203 228 12795780 10.1046/j.1365-2710.2003.00487.x 1:CAS:528:DC%2BD3sXlvV2rsLw%3D
4. F Leonessa R Clarke 2003 ATP binding cassette transporters and drug resistance in breast cancer Endocr Relat Cancer 10 1 43 73 12653670 10.1677/erc.0.0100043 1:CAS:528:DC%2BD3sXksVahtLk%3D
5. BI Sikic 1999 Modulation of multidrug resistance: a paradigm for translational clinical research Oncology (Williston Park) 13 5A 183 187 1:STN:280:DyaK1M3pvFSltw%3D%3D
6. BI Sikic GA Fisher BL Lum J Halsey L Beketic-Oreskovic G Chen 1997 Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein Cancer Chemother Pharmacol 40 Suppl S13 S19 9272128 10.1007/s002800051055 1:CAS:528:DyaK2sXlsVyrsLo%3D
7. SV Ambudkar S Dey CA Hrycyna M Ramachandra I Pastan MM Gottesman 1999 Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 39 361 398 10331089 10.1146/annurev.pharmtox.39.1.361 1:CAS:528:DyaK1MXjtVejtLo%3D
8. L Lu F Leonessa R Clarke IW Wainer 2001 Competitive and allosteric interactions in ligand binding to P-glycoprotein as observed on an immobilized P-glycoprotein liquid chromatographic stationary phase Mol Pharmacol 59 1 62 68 11125025 1:CAS:528:DC%2BD3MXns1Cluw%3D%3D
9. BJ Trock F Leonessa R Clarke 1997 Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance J Natl Cancer Inst 89 13 917 931 9214671 10.1093/jnci/89.13.917 1:STN:280:DyaK2szlslensA%3D%3D
10. E Mechetner A Kyshtoobayeva S Zonis H Kim R Stroup R Garcia RJ Parker JP Fruehauf 1998 Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin Clin Cancer Res 4 2 389 398 9516927 1:CAS:528:DyaK1cXhtlSmsbs%3D
11. H Burger JA Foekens MP Look ME Meijer-van Gelder JG Klijn EA Wiemer G Stoter K Nooter 2003 RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response Clin Cancer Res 9 2 827 836 12576456 1:CAS:528:DC%2BD3sXhtVKksbc%3D
12. HS Chan G DeBoer JJ Thiessen A Budning JE Kingston JM O'Brien G Koren E Giesbrecht G Haddad Z Verjee, et al. 1996 Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation Clin Cancer Res 2 9 1499 1508 9816326 1:CAS:528:DyaK28XmtFSrt7o%3D
13. V Fischer A Rodriguez-Gascon F Heitz R Tynes C Hauck D Cohen AE Vickers 1998 The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite Drug Metab Dispos 26 8 802 811 9698296 1:CAS:528:DyaK1cXlsVSqs7Y%3D
14. A Gruber M Bjorkholm L Brinch S Evensen B Gustavsson M Hedenus G Juliusson E Lofvenberg I Nesthus B Simonsson, et al. 2003 A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia Leuk Res 27 4 323 328 12531223 10.1016/S0145-2126(02)00181-9 1:CAS:528: DC%2BD3sXislylsg%3D%3D
15. AH Dantzig RL Shepard J Cao KL Law WJ Ehlhardt TM Baughman TF Bumol JJ Starling 1996 Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979 Cancer Res 56 18 4171 4179 8797588 1:CAS:528:DyaK28XlslGgtrg%3D
16. D Toppmeyer AD Seidman M Pollak C Russell K Tkaczuk S Verma B Overmoyer V Garg E Ette MW Harding, et al. 2002 Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel Clin Cancer Res 8 3 670 678 11895894 1:CAS:528:DC%2BD38XislOqt7s%3D
17. JJ Starling RL Shepard J Cao KL Law BH Norman JS Kroin WJ Ehlhardt TM Baughman MA Winter MG Bell, et al. 1997 Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein Adv Enzyme Regul 37 335 347 9381979 10.1016/S0065-2571(96)00021-0 1:STN:280:DyaK1c%2FitV2msg%3D%3D
18. A Stewart J Steiner G Mellows B Laguda D Norris P Bevan 2000 Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration Clin Cancer Res 6 11 4186 4191 11106230 1:CAS:528:DC%2BD3cXovVSgtLc%3D
19. RL Shepard J Cao JJ Starling AH Dantzig 2003 Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979 Int J Cancer 103 1 121 125 12455064 10.1002/ijc.10792 1:CAS:528:DC%2BD38Xptl2ht7w%3D
20. EH Rubin DP de Alwis I Pouliquen L Green P Marder Y Lin R Musanti SL Grospe SL Smith DL Toppmeyer, et al. 2002 A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar•3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies Clin Cancer Res 8 12 3710 3717 12473580 1:CAS:528: DC%2BD38XpslCjtrk%3D
21. AM Oza 2002 Clinical development of P glycoprotein modulators in oncology Novartis Found Symp 243 103 115 11990771 10.1002/0470846356.ch8 1:CAS:528:DC%2BD38XjvVKit7k%3D discussion 115-118, 180-185
22. K Abu Ajaj F Kratz 2009 Development of dual-acting prodrugs for circumventing multidrug resistance Bioorg Med Chem Lett 19 3 955 1000 10.1016/j.bmcl.2008.11.063
23. VS Velingkar VD Dandekar 2010 Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) in cancer using chemosensitizers Int J Pharm Sci Res 1 2 104 111 1:CAS:528:DC%2BC3cXhtlKqur7M
24. BF Sloane S Yan I Podgorski BE Linebaugh ML Cher J Mai D Cavallo-Medved M Sameni J Dosescu K Moin 2005 Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment Semin Cancer Biol 15 2 149 157 15652460 10.1016/j.semcancer.2004.08.001 1:CAS:528:DC%2BD2MXisFOisg%3D%3D
25. F Kratz 2008 Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J Control Release 132 3 171 183 18582981 10.1016/j.jconrel.2008.05.010 1:CAS:528:DC%2BD1cXhsVensLvP
26. F Kratz U Beyer MT Schütte 1999 Drug-polymer conjugates containing acid-cleavable bonds Crit Rev Ther Drug Carrier Syst 16 3 245 288 10706520 1:CAS:528:DyaK1MXksFelsr8%3D
27. H Maeda J Wu T Sawa Y Matsumura K Hori 2000 Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J Control Release 65 1-2 271 284 10699287 10.1016/S0168-3659(99)00248-5 1:CAS:528: DC%2BD3cXhtl2qsLo%3D
28. F Kratz 2007 DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials Expert Opin Investig Drugs 16 6 855 866 17501697 10.1517/13543784.16.6.855 1:CAS:528:DC%2BD2sXltlOju7Y%3D
29. F Kratz IA Muller C Ryppa A Warnecke 2008 Prodrug strategies in anticancer chemotherapy ChemMedChem 3 1 20 53 17963208 10.1002/cmdc.200700159 1:CAS:528:DC%2BD1cXlt1KqsrY%3D
30. VG Kaklamani WJ Gradishar 2003 Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer 4 Suppl 1 S26 S33 12756076 10.3816/CBC.2003.s.012 1:CAS:528: DC%2BD3sXksV2ntr8%3D
31. C Zhang S Sarshar EJ Moran S Krane JC Rodarte KD Benbatoul R Dixon AM Mjalli 2000 2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 2 Bioorg Med Chem Lett 10 23 2603 2605 11128633 10.1016/S0960-894X(00)00521-7 1:CAS:528:DC%2BD3cXotlant70%3D
32. MJ Newman JC Rodarte KD Benbatoul SJ Romano C Zhang S Krane EJ Moran RT Uyeda R Dixon ES Guns, et al. 2000 Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance Cancer Res 60 11 2964 2972 10850444 1:CAS:528:DC%2BD3cXjvFOlt74%3D
33. P Ruff DA Vorobiof JP Jordaan GS Demetriou SD Moodley AL Nosworthy ID Werner J Raats LJ Burgess 2009 A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen Cancer Chemother Pharmacol 64 4 763 768 19241078 10.1007/s00280-009-0925-9 1:CAS:528:DC%2BD1MXptFCksLo%3D
34. F Morschhauser PL Zinzani M Burgess L Sloots F Bouafia C Dumontet 2007 Phase I/II trial of a P-glycoprotein inhibitor, zosuquidar•3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma Leuk Lymphoma 48 4 708 715 17454628 10.1080/10428190701190169 1:CAS:528:DC%2BD2sXnsVSjurw%3D
35. CJ Barnett B Huff ME Kobierski M Letourneau TM Wilson 2004 Stereochemistry of C-6 nucleophilic displacements on 1,1- difluorocyclopropyldibenzosuberanyl substrates. An improved synthesis of multidrug resistance modulator LY335979 trihydrochloride J Org Chem 69 22 7653 7660 15497993 10.1021/jo049051v 1:CAS:528:DC%2BD2cXotVCisbw%3D
36. PCA Rodrigues K Scheuermann C Stockmar G Maier HH Fiebig C Unger R Mülhaupt F Kratz 2003 Synthesis and in vitro efficacy of acid-sensitive poly(ethylene glycol) paclitaxel conjugates Bioorg Med Chem Lett 13 3 355 360 12882225 10.1016/S0960-894X(02)01002-8 1:CAS:528:DC%2BD3sXit12rt7g%3D
37. F Kratz A Warnecke K Scheuermann C Stockmar J Schwab P Lazar P Drückes N Esser J Drevs D Rognan, et al. 2002 Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound J Med Chem 45 5523 5533 12459020 10.1021/jm020276c 1:CAS:528:DC%2BD38XosFWhurs%3D
38. H Naundorf EC Rewasowa I Fichtner B Buttner M Becker M Gorlich 1992 Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives Breast Cancer Res Treat 23 1-2 87 95 1446057 10.1007/BF01831480 1:STN:280:DyaK3s%2FnsF2rsw%3D%3D
39. U Stein W Walther M Lemm H Naundorf I Fichtner 1997 Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo Int J Cancer 72 5 885 891 9311609 10.1002/(SICI)1097- 0215(19970904)72:5<885::AID-IJC28>3.0.CO;2-6 1:CAS:528:DyaK2sXmtVKqsb8%3D
40. B Elsadek R Graeser N Esser C Schafer-Obodozie C Tsurumi K Abu Ajaj A Warnecke C Unger T Saleem F Kratz 2011 In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP) Prostate Cancer Prostatic Dis 14 1 14 21 21042336 10.1038/pcan.2010.43 1:CAS:528:DC%2BC3MXhs1ylsrY%3D
41. JS Lee K Paull M Alvarez C Hose A Monks M Grever AT Fojo SE Bates 1994 Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen Mol Pharmacol 46 4 627 638 7969041 1:CAS:528:DyaK2MXitVantbw%3D
42. F Kratz R Mueller-Driver I Hofmann J Drevs C Unger 2000 A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy J Med Chem 43 7 1253 1256 10753462 10.1021/jm9905864 1:CAS:528:DC%2BD3cXhsFyhtLw%3D
43. S Del Vecchio M Salvatore 2004 99mTc-MIBI in the evaluation of breast cancer biology Eur J Nucl Med Mol Imaging 31 Suppl 1 S88 S96 15105972 10.1007/s00259-004-1530-0
44. S Del Vecchio A Zannetti L Aloj M Salvatore 2003 MIBI as prognostic factor in breast cancer Q J Nucl Med 47 1 46 50 12714954 1:STN:280: DC%2BD3s7psFGgsQ%3D%3D
45. JH Yoon HS Bom HC Song JH Lee YJ Jaegal 1999 Double-phase Tc-99m sestamibi scintimammography to assess angiogenesis and P-glycoprotein expression in patients with untreated breast cancer Clin Nucl Med 24 5 314 318 10232467 10.1097/00003072-199905000-00003 1:STN:280:DyaK1M3kslChtQ%3D%3D